+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "respiratory disease"

U1. Protein Production Platform Unit (PPP)

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request
U1 PPP-Insect cells-Baculovirus as cell factoriesU1 PPP-Insect cells-Baculovirus as cell factories
U1 PPP-7L Bioreactor for protein productionU1 PPP-7L Bioreactor for protein production
U1 PPP–AKTA Purifier equipment for protein purificationU1 PPP–AKTA Purifier equipment for protein purification
U1 teamU1 team

Description

The PPP Unit is at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB). It counts with the necessary facilities for the design, production, and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, led by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer a “tailored” service for the design, production, and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic, X-ray crystallography, and Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, another with all the necessary equipment for molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification for standard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Brochure Unit 1 – PPP

–

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % THE OF OPENNESS EACH SERVICE

U1. Services & Rates

News U1

10 Dec

NANBIOSIS Unit invited to PEGS, the Protein & Antibody Engineering Summit

NANBIOSIS’s Protein Production Platform showcased innovations in protein engineering at PEGS Europe 2024, featuring talks, posters, and session moderation. Barcelona, november 2024. Last month, the NBT group and Unit 1 of NANBIOSIS (Protein Production Platform, PPP), from CIBER-BBN and IBB-UAB, was invited once again to participate in the prestigious PEGS Europe conference. PEGS Europe, a prestigous conference This year, the 16th PEGS Europe conference was held in Barcelona from November 5th to 7th. PEGS, or the Protein & Antibody Engineering Summit, is organized by the Cambridge Healthtech Institute (CHI) and is renowned for its focus on protein engineering and its[...]

18 Nov

The Protein Production Platform (PPP) at the UAB Innovation Fair

The PPP advances antimicrobial peptide research, forging partnerships to combat antibiotic resistance and prevent medical device-related infections. Barcelona, october 2024. During Antibiotic Awareness Week, we spotlight the Protein Production Platform (PPP) at NANBIOSIS Unit 1 for its pivotal role in combating antimicrobial resistance. At the recent UAB Innovation Fair, the PPP showcased its cutting-edge technologies and established collaborations with experts in bacterial biofilms and nanomaterials. Together, they aim to develop innovative antimicrobial peptides as alternatives to traditional antibiotics, targeting nosocomial infections linked to medical devices. These efforts underscore the critical importance of advancing research and partnerships to address one of[...]

10 Oct

Knowdlege growth: A chart-guide for cloning, production, purification, and characterization of recombinant proteins from prokaryotic systems

The Nanobiotechnology Group and NANBIOSIS PPP have created a poster-guide for recombinant protein cloning, production, and purification in prokaryotic systems. Barcelona, october 2024. The Nanobiotechnology Group, led by Prof. Villaverde, in collaboration with the NANBIOSIS Unit 1, Protein Production Platform (PPP), directed by Dr. Ferrer-Miralles, has created an in-depth guide in the form of a poster that compiles key strategies for cloning, production, purification, and characterization of recombinant proteins expressed in prokaryotic systems. Drawing from their vast experience in the field, they have meticulously outlined techniques and best practices to address common challenges and optimize every stage of the process.[...]

09 Oct

Harnessing Nanotechnology in protein research: Insights from Dr. Neus Ferrer on new ways of fighting antimicrobial resistance

Dr. Neus Ferrer explores nanotechnology in protein research to combat antimicrobial resistance, focusing on innovative solutions using lysins and other recombinant proteins. Barcelona, October 2024. In celebration of Nanotechnology Day, we take a closer look at the cutting-edge work of Dr. Neus Ferrer, director of the Unit 1, Protein Production Platform (PPP), at NANBIOSIS. Specializing in recombinant protein synthesis, Dr. Ferrer’s research tackles critical challenges in healthcare, particularly antimicrobial resistance, often referred to as the “new pandemic”. Through advanced nanotechnology approaches, her team in develops innovative solutions that could revolutionize treatment options in biomedicine and beyond. The interview begins… Interviewer:[...]

04 Apr

Protein-only Materials offer a new hope in colorectal cancer treatment

Breakthrough colorectal cancer treatment unveiled by NANBIOSIS Units promises enhanced precision & efficacy in targeted cancer therapies. March 2024, UAB/Institut de Recerca Sant Pau/CIBER-BBN (Barcelona) As we leave World Colorectal Cancer Day 2024 behind, marked on March 31st, there have been significant highlights in cancer treatment, a field in which targeted therapies are playing a crucial role. In this context, researchers from the Nanobiotechnology team, at the Institut de Biotecnologia i de Biomedicina from Universitat Autònoma de Barcelona, led by Prof. Antonio Villaverde, in collaboration with the Oncogenesis and Antitumor Drugs team led by Prof. Ramón Mangues at Institut d[...]

05 Mar

New immunization research for SARS-CoV-2 with the collaboration of NANBIOSIS

This novel immunization platform, recently published in ACS, triggers potent antivirus response, promising efficient and cost-effective vaccination. March 2024, UAB/Vall d’Hebron Research Institute/CIBER-BBN (Barcelona) The battle against infectious diseases demands innovative solutions. The world is especially aware of this fact after facing threats such as the SARS-CoV-2 pandemic. In a very recent publication in ACS Materials Letters, researchers from the Universitat Autònoma de Barcelona (UAB) and Hospital de Sant Pau, both within the CIBER-BBN, have achieved a significant milestone in vaccine development. Their study, conducted in partnership with international teams as well as NANBIOSIS, has introduced a novel immunization approac[...]

27 Dec

NANBIOSIS U1_Protein Production Platform expands its facilities at the Autonomous University of Barcelona, strengthening its capabilities.

NANBIOSIS Unit 1 Protein Production Platform (PPP) of CIBER-BBN and UAB, has taken a significant step towards enhancing its service capabilities in the field of recombinant protein production and purification. Until now, due to space constraints at the Institute of Biotechnology and Biomedicine (IBB), U1’s activities were confined to half of a small laboratory. However, thanks to the ongoing commitment of the center to bolster the PPP’s activities, this unit has gained access to a laboratory, along with an office, exclusively designated for the platform within the IBB premises, creating an optimal environment for the process of protein production and[...]

20 Dec

Good News! Protein Nanoparticles with a New Ligand Select and Destroy Tumor-associated Fibroblasts”

With the participation of two units of NANBIOSIS ICTS and the expertise of the scientists managing these units The study, fruit of the collaboration between the Nanotechnology group of the Institute of Biotechnology and Biomedicine (IBB-UAB), led by Prof. Antonio Villaverde, and the Oncogenesis and Antitumor Drugs group of the Sant Pau Research Institute, led by Dr. Ramon Mangues, both members of CIBER-BBN, has made significant progress by identifying the natural ligand PDGFD as an effective tool to target protein nanoparticles to tumor-associated fibroblasts that overexpress the PDGFR-β receptor. Given the relevance of the discovery, this technology has been intellectually[...]

U1-Protein Production Platform - PPP
• Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Dr. Mariana Köber mkober@icmab.es
    • Scientific Coordinator:  Dr. Elisabet González Mira egonzalez@icmab.es
    • Technical Coordinator: José Amable Bernabé jabernabe@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

U6. Compressed fluids based biomaterials processing platformU6. Compressed fluids based biomaterials processing platform
U6. Dynamic light scattering for particle size and Z potential measurementsU6. Dynamic light scattering for particle size and Z potential measurements
U6. Compressed fluids based biomaterials processingU6. Compressed fluids based biomaterials processing

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Prof. Nora Ventosa, current director of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing, and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano-, and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization, and crystalline purity). This example shows one of the singularities of this unit: that it counts with CF–based plants at different scales, from mL to L, which allows process development by QbD and process scale-up.
The NANBIOSIS Unit 6 works under the ISO9001 certification for standard quality control system
 




 




 



		
		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U6. Services & Rates

		
		

			




		

		
		
	

		
		

		
		

		
		

		
		

		
		
	

		
		
News U6
25 Mar
New breakthrough in preventing infections in biomedical implants
A new TPU surface modification with an antimicrobial protein prevents biofilm formation in implants, offering an alternative to antibiotics and metal coatings. Barcelona, february 2025. Infections associated with medical implants are a serious health issue. A new study presents a chemical modification of thermoplastic polyurethane (TPU) with an antimicrobial protein that reduces the formation of biofilms of multidrug-resistant bacteria, offering an alternative to antibiotics and metal coatings in these devices. A team of researchers has developed a new strategy to chemically modify TPU, a material widely used in medical devices, to endow it with antibacterial properties and prevent infections associated[...]
28 Feb
Awareness and research on Fabry Disease with a special event at ICMAB
Join us on April 29 at ICMAB for “Fabry Connections” to explore research, patient insights, and future challenges in Fabry disease. Register now! Barcelona, february 2025. Today, February 28, World Rare Disease Day, NANBIOSIS reaffirms its commitment to advancing research and raising awareness of rare diseases such as Fabry disease. In this context, we are pleased to invite researchers, healthcare professionals, patient associations, and individuals affected by Fabry disease to the event “Fabry Connections: Science, Patients, and Future”, which will take place on Tuesday, April 29, 2025, at the ICMAB-CSIC. This event is organized by our Unit 6, Biomaterial Processing[...]
05 Feb
New Consequences in Familial Hypercholesterolemia due to Abnormal LDL
Misfolded ApoB100 in LDL promotes plaque buildup in familial hypercholesterolemia, raising cardiovascular risk. Structural preservation may aid prevention. Barcelona, febrero 2025. As recently published in the ICMAB webpage, a new study links ApoB100 protein structure (a key protein found in low-density lipoprotein, LDL, often called “bad cholesterol”) to increased cardiovascular risk in familial hypercholesterolemia. The study, led by IIBB-CSIC and CIBER, with the contribution of ICMAB’s SOFT Service (with NANBIOSIS Unit 6 at its core), shows that the protein structure directly contributes to an increased tendency to aggregate and form atherosclerotic plaques in patients with familial hypercholesterolemia. In these patients,[...]
29 Jan
A Breakthrough Therapy for Fabry Disease: nanoGLA Demonstrates Promising Results
Fabry disease therapy nanoGLA, developed by NANBIOSIS and our partners, shows superior efficacy in preclinical trials, targeting systemic and brain symptoms. Barcelona, january 2025. An international research team led by the Institute of Materials Science of Barcelona (ICMAB-CSIC) and CIBER-BBN, in collaboration with the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), has developed a groundbreaking nanotechnology-based therapy called nanoGLA for the treatment of Fabry disease. The innovative solution has shown remarkable efficacy in preclinical studies and has been published in the open-access journal Science Advances (see below for reference links). What is Fabry disease? Fabry disease is a rare genetic[...]
23 Oct
attendants of the course held at ICMAB
The Soft Lab held a new edition of the course on characterization and preparation of particulate materials
José Amable Bernabé, Technical Coordinator of Unit 6, hosted a course on “Characterization techniques for particulate materials”. Barcelona, october 2024. For yet another year, José Amable Bernabé, of the Soft Materials Service at ICMAB and Technical Coordinator of NANBIOSIS Unit 6, offered this course. The course was an explanation of different techniques to characterize nanoparticles and particulate matter, including the fundamentals of these techniques, sample preparation, practical examples and results interpretation. The course is offered every year through the CSIC training courses offered every year for all its staff, as reported in ICMAB webpage. Soft Materials Service The Soft Materials Service provides[...]
01 Mar
Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases
NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing extracellular vesicles and liposomes, offering hope to patients. 1 March 2024, Vall d’Hebron Research Institute/ICMAB-CSIC (Barcelona) Lysosomal Storage Diseases (LSDs) encompass a group of rare disorders caused by mutations in lysosomal proteins. These mutations can lead to dysfunctional proteins responsible for breaking down cellular materials, resulting in the accumulation of deposits. Such accumulations can manifest in various neurological symptoms, ranging from progressive neurodegeneration to severe cognitive impairment. Often emerging in childhood, LSDs tragically culminate in premature death for many patients. Currently, up to 14 subtypes of LSDs can be treated[...]
21 Feb
The NABIHEAL Project Pioneers Wound Healing with New Biomimetic Matrices
Nearly 40 scientists across 7 countries are pioneering this breakthrough in wound healing using a nobel and affordable bio-inspired, anti-bacterial matrix. In addition to the vast consortium, the project also comprises 5 small and medium-sized enterprises (SMEs) and 9 academic institutions. These were convened last February at the University of Granada to share insights, progress, and strategies. According to an article published by UGR at the beginning of this month, about 40 researchers involved in the project have attended a meeting to share results and progress. The Horizon Europe project NABIHEAL, coordinated by the Biomedical Research Networking Center (CIBER) at[...]
27 Oct
Technical seminar on materials characterisation equipment
The Service-SOFT/U6 Nanbiosis ICTS (of CIBER-BBN and ICMAB-CSIC) together with the company NANE are organising a technical seminar on materials characterisation equipment. In this seminar, different techniques for the characterisation of particulate materials such as DLS, NTA, Laser Diffraction, Morphology will be discussed. Limited places. You can register at this link Link to the program: here Date: 08th of November Place: Institute of Materials Science of Barcelona (ICMAB) -CSIC – Conference room[...]

		
		
	

											

											U6-Biomaterial Processing and Nanostructuring Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U10. Drug Formulation

												

		
		
Ciber bbn


U10. Drug Formulation


    

  • 

      

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
      • 

    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
      • 

    • Entities: Universidad del País Vasco (UPV/EHU)
      • 

    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
      • 

    • Phone: +34 653593042
      • 

    • Fax: +34 945 013040
      • 

    • Web: NANOBIOCEL UPV/EHU
      • 

    

    • 









UPV-EHU






Order request

		
		
	

		
		
U10. Drug Formulation-Particle_size_analyzerU10. Drug Formulation-Particle_size_analyzer
U10. Drug Formulation-LOTE 4 CALCEINA 10X 2BISU10. Drug Formulation-LOTE 4 CALCEINA 10X 2BIS
U10. Drug Formulation- Dissolution_rate_determination_equipmentU10. Drug Formulation- Dissolution_rate_determination_equipment


Description


Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.


This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.


The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.


The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.


One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency 



		
		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U10. Services & Rates

		
		

			




		

		
		
	

		
		

		
		

		
		

		
		

		
		
	

		
		
News U10
28 Feb
Advancing new treatments for Retinitis Pigmentosa within NANBIOSIS
NANBIOSIS Unit 10 develops lipid-based nanoparticles for gene and drug delivery, aiming for cost-effective, non-invasive treatments for retinitis pigmentosa. Vitoria, february 2025. Retinitis pigmentosa (RP) is a congenital rare disease that leads to progressive and irreversible vision loss. Both genetic mutations and inflammation contribute significantly to the progression of the disease. Researchers from the Drug [...]
11 Sep
Gene Therapy for Cystic Fibrosis: new inspiring scientific collaboration
Researchers are advancing gene therapies for cystic fibrosis using non-viral delivery methods, focusing on patient needs and innovative treatments. Basque Country, September, 2024 – As the world comes together to mark World Cystic Fibrosis Day, from NANBIOSIS we want to highlight the collaborative efforts between our Unit 10 “Drug Formulation” (U10), the University of the [...]
09 Sep
New gene therapy for Cystic Fibrosis: an interview with Lucía Enríquez
Vasque Country, September, 2024 – In this interview, Lucía Enríquez, a PhD researcher at NANBIOSIS Unit 10, discusses her work on gene therapies for cystic fibrosis, a genetic disease that mainly affects the lungs. Her research focuses on using non-viral vectors to deliver gene-editing tools, like Prime Editing, a variation of CRISPR-Cas9, to correct mutations [...]
27 Jun
Prof. Jose Luis Pedraz, new “Académico de Número” of the Spanish Royal National Academy of Pharmacy
Madrid, June, 2024 – In a distinguished ceremony held at the Spanish Royal National Academy of Pharmacy (Real Academia Nacional de Farmacia), Professor Jose Luis Pedraz Muñoz, a prominent figure at the University of the Basque Country, was officially inducted as an “Académico de Número”. The highest position within the Royal National Academy of Pharmacy. [...]
13 Nov
Rosa Hernández of the NanoBioCel group-NANBIOSIS U10 has received the Female Talent Award 2023 Women and Science
On Thursday, November 2, the Female Talent Award, in the category of Women and Science, was awarded to Rosa Hernández from the NanoBioCel group of CIBER BBN and the U10 Drug Formulation Unit. The award is given by AMPEA (Association of Professional and Business Women of Alava). In her award speech, Rosa Hernández, highlighted that [...]
08 Nov
Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.
2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed [...]
15 Oct
Developing Support Technologies for adressing traslational gaps in regenerative medicine.
On the 20th of October, CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit organises the Conference “Developping support technologies for adressing traslational gaps in regenerative medicine” by Dr. James-J Yoo. The Conference will take place in the Assembly hall of the Faculty of Pharmacy on Friday 20th of October, 2023 from 12:00 to 13:00, [...]
02 Oct
3D Printing and Bioprinting for Pharmaceutical and Medical Applications
Researchers of CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma have edited the book “3D Printing and Bioprinting for Pharmaceutical and Medical Applications” The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D [...]
22 Jun
The role of microfluidics and 3D-bioprinting in the future of exosome therapy. A high impact review
Researchers of the NanoBioCel research group of the University of the Basque Country (UPV/EHU) and CIBER BBN, belonging to NANBIOSIS U10 Drug Formulation, Bioaraba, and CONICET Foundation of Argentina, have collaborated in a studio entitled: “The role of microfluidics and 3D-bioprinting in the future of the exosome therapy” which has been published in the journal [...]
23 Nov
Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference
Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference. On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in [...]

		
		
	

											

																						

												
												•
												Read More